Skip to content

The effect of astaxanthin on cognitive and physical function A randomized, double blind, placebo-controlled study

The effect of astaxanthin on cognitive and physical function A randomized, double blind, placebo-controlled study - The effect of astaxanthin on cognitive and physical function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028775
Enrollment
40
Registered
2017-08-22
Start date
2017-09-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

Study food 12weeks Placebo 12weeks

Sponsors

Miura Clinic, Medical Corporation Kanonkai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy males and females aged 60 to 79 years old 2) Subjects who are aware of declining cognitive ability 3) Subjects who have 24 points or more on MMSE score 4) Subjects who are aware of declining physical strength

Exclusion criteria

Exclusion criteria: 1) Subjects with dementia (including Alzhheimer type dementia) 2) Subjects who have symptoms of mild cognitive impairment (MCI) 3) Subjects who had treatment, hospitalization, and/or surgery due to Stroke, Subarachnoid hemorrhage, Cerebral infarction, Cerebral hemorrhage, Brain contusion, and/or Head trauma 4) Subjects with chronic or acute infection 5) Subjects who have current disease or history of hepatitis 6) Subjects who are attending a hospital by following diseases or has medical history of Attack, Seizures, Diabetes, Thyroid dysfunction, Blood dialysis, Uremia, Anuria, Inner ear disease (Meniere's disease and so on), and/or Asthma 7) Subjects with medical history of serious disorder (Liver disease, Kidney disease, Hypertension, Ischemic heart disease, Impaired glucose tolerance, Gastrointestinal disease, Peripheral vascular disease, and so on) 8) Subjects with Cardiorespiratory disorder 9) Subjects who have abnormal test value in liver function and kidney function 10) Subjects who have undergone surgery of the gastrointestinal tract 11) Subjects with food, drug allergy 12) Subjects who have received the neuropsychological tests in hospital 13) Subjects with movement disorders, visual impairment, hearing impairment 14) Subjects who have experience to feel sick by watching shiny light 15) Subjects on a diet 16) Subjects with excessive smoking habit 17) Subjects who ingested in excessive alcohol or cannot abstain from alcohol from the day before the study to the day of study 18) Subjects who take healthy foods, quasi-drugs and pharmaceuticals (including OTC, prescription medicine) containing ingredients contained in the test food 19) Subjects participating in other clinical trials at the start of the present study 20) Subjects who the investigator deems inappropriate

Design outcomes

Primary

MeasureTime frame
Cognitive function test, Physical function test

Secondary

MeasureTime frame
Feeling questionnaire

Countries

Japan

Contacts

Public ContactMakoto Terashima

Oneness support Co., Ltd. Clinical trial Division

mterashima@oneness-sup.co.jp06-4801-8917

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026